Safety and efficacy of infliximab and corticosteroid therapy in checkpoint inhibitor-induced colitis

Emilie Kristine Dahl*, Osama Karim Abed, Jens Kjeldsen, Marco Donia, Inge Marie Svane, Anders Dige, Jørgen Steen Agnholt, Jacob Tveiten Bjerrum, Jakob Benedict Seidelin

*Corresponding author for this work

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

13 Citations (Scopus)

Abstract

Background: Cancer patients treated with immune check point inhibitors are at risk of developing severe colitis. However, the efficacy and safety of treatment of severe colitis is poorly understood. Aims: To explore the safety and efficacy of infliximab and corticosteroids in severe immune-mediated enterocolitis (IMC). Method: We performed a nationwide retrospective cohort study on 140 cancer patients treated with infliximab due to IMC in Denmark from 2011 to 2021. Results: The rate of complete remission with infliximab was 52% after one dose, increasing to 73% after two or more doses. Thirteen patients (10%) required additional treatment with vedolizumab. Patients were heavily exposed to corticosteroids and received a median accumulated dose of 3978 mg (interquartile range [IQR] 2552–6414). Age- and cancer-adjusted Cox regression analysis found that a high dose of prednisolone at start of tapering ≥75 mg/day was associated with increased mortality (HR 1.67, 1.04–2.69, p = 0.035). Patients responding to infliximab experienced an improvement of symptoms after 3 days (IQR 2–4) and complete remission after 31 days (IQR 14–61). Twenty-four percent required hospitalisation for infection during treatment for IMC, lasting 7 days (median). Secondary gastrointestinal infections occurred in 16%, with Clostridioides difficile being most common (64%). Further, 10% had a thromboembolic event during the first 90 days after infliximab treatment. Conclusions: Infliximab led to complete resolution of symptoms in 73% of patients with IMC. High prednisolone dose at tapering was associated with increased mortality rate and a high incidence of infections and hospitalisations in patients with severe IMC. We suggest optimised infliximab treatment before escalation of steroid doses.

Original languageEnglish
JournalAlimentary Pharmacology and Therapeutics
Volume56
Issue9
Pages (from-to)1370-1382
ISSN0269-2813
DOIs
Publication statusPublished - Nov 2022

Fingerprint

Dive into the research topics of 'Safety and efficacy of infliximab and corticosteroid therapy in checkpoint inhibitor-induced colitis'. Together they form a unique fingerprint.

Cite this